(Q35043121)

6 August 2017

1 reference

title

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider (English)

1 reference

6 August 2017

1 reference

Richard Vile

1

1 reference

PubMed ID

12522445

6 August 2017

Dale Ando

series ordinal

2

1 reference

PubMed ID

12522445

6 August 2017

David Kirn

series ordinal

3

1 reference

6 August 2017

1 December 2002

1 reference

6 August 2017

1 reference

6 August 2017

9

1 reference

6 August 2017

1062-1067

1 reference

6 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700548

6 August 2017

0 references

cites work

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Antineoplasic activity of parvoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Poxvirus vectors: orphaned and underappreciated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Modeling and analysis of a virus that replicates selectively in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Adenovirus 2 Ip+ locus codes for a 19 kd tumor antigen that plays an essential role in cell transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

7 January 2021

Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

7 January 2021

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700548

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700548

1 reference

6 August 2017

1 reference

PubMed ID

12522445